Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win
Enanta Pharmaceuticals is asking the Federal Circuit to rethink its June refusal to revive a patent it had asserted against Pfizer over its COVID-19 treatment Paxlovid, saying the court acted beyond...To view the full article, register now.
Already a subscriber? Click here to view full article